Aurora Cannabis announced a partnership with Mitacs, a not-for-profit research group for a study alongside the University of Alberta on the health outcomes associated with cannabis use.
Aurora Cannabis (TSX:ACB; OTCQB:ACBFF) announced a partnership with Mitacs, a not-for-profit research group for a study alongside the University of Alberta on the health outcomes associated with cannabis use.
As quoted in the press release:
Despite a rapidly growing body of scientific and anecdotal evidence supporting the therapeutic benefits of cannabis, comprehensive patient cohort studies into health outcomes related to cannabis use are lacking. Consequently, many physicians who are attempting to accommodate requests from patients have limited information to support decision making in regard to prescribing cannabis-based therapies.
The research project will study the health outcomes of a significant data repository that combines patient-reported outcome measures and physician-based medical assessments, collected from 29,000 Canadian patients who have been prescribed medical cannabis. The researchers intend to perform multiple population-based observational studies to characterize the population, acute and chronic conditions, the exposure of medical cannabis, participant ratings of symptom improvement and satisfaction with treatment, as well as side effects, adverse events and long-term beneficial or detrimental effects.